mohammad ARIF, Fatma HUSSAIN, Munir AHMAD

The prevalence of diabetic retinopathy in Faisalabad, Pakistan: a population-based study

To determine the plasma prevalence and characteristics of diabetic retinopathy (DR) among Pakistani diabetic patients in the Faisalabad region. Diabetes mellitus (DM) is a major cause of avoidable blindness worldwide. People with DR are 25 times more likely to become blind than nondiabetics. Materials and methods: The incidence of retinopathy was determined in 1524 people with diabetes during April 2008 and January 2009. Physician-diagnosed diabetic patients underwent an eye examination by ophthalmoscopy and fundus photography. Participants were also interviewed and examined in order to determine demographic characteristics and medical history. Results: Of the 1524 patients screened, 183 (12%) had DR. Of these, 7% (106) had nonproliferative DR and 5% (77) had proliferative DR. Clinically significant macular edema was detected in 1.2% of patients. The prevalence of DR was higher in patients with type 1 diabetes than in those with type 2 diabetes. This difference was found to be statistically insignificant, however (P > 0.05). About 3% of the diabetic patients in our study had a family history of diabetes and only 6% had a history of regular eye examinations. Conclusion: This study demonstrated a high prevalence of DR in Faisalabad. An organized approach is needed to ensure adequate prevention and treatment in patients with diabetes.

Anahtar Kelimeler:

Key words: Retinopathy, diabetes mellitus, hyperglycemia

The prevalence of diabetic retinopathy in Faisalabad, Pakistan: a population-based study

Keywords:

Key words: Retinopathy, diabetes mellitus, hyperglycemia,

PDF

___

Pota M, Bandello F. Diabetic retinopathy. A clinical update. Diabetologia 2002; 45: 1617-34.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Th e Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-32. Klein R, Klein BE, Moss SE. Th e Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and high risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-6.
Th e Diabetes Control and Complications Trial Research Group. Th e eff ect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86. 5. Wild S, Gojka R, Anders G, Richard S, Hilary K. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
Abdul B, Williams R. Promoting care in underserved communities: launching World Diabetes Day in Karachi. Diabetes Voice 2006; 51: 46-7.
Basit A, Hydrie ZI, Rubina Ahmedani MYH, Masood Q. Frequency of chronic complications of Type-II diabetes. J Coll Physicians Surg Pak 2004; 14: 79-83. 8. Shera AS, Jawad F, Maqsood A, Jamal S, Azfar M, Ahmed U. Prevalence of chronic complications and associated factors in type 2 diabetes. J Pak Med Assoc 2004; 54: 54-9. 9. Kayani H, Rehan N, Ullah N. Frequency of retinopathy among diabetics admitted in a teaching hospital of Lahore. J Ayub Med Coll Abbotabad 2003; 15: 53-6.
Khan AJ. Prevalence of diabetic retinopathy in Pakistani subjects. A pilot study. J Pak Med Assoc 1991; 41: 49-50.
Aziz TM. Incidence of ophthalmic problems in diabetic patients in Pakistan. A preliminary report. Ophthalmic Practice 1996; 2: 6-8.
Jahangir S. Diabetic retinopathy in Pakistani diabetics. Pak J Ophthalmol 1989; 5: 77-9.
Mohammad Z, Khan MD. Incidence of ocular complications of diabetes mellitus in Pakistan. Pak J Ophthalmol 1992; 8: 7-11.
Jamal-u-Din, Qureshi MB, Khan AJ, Khan MD, Ahmad K. Prevalence of diabetic retinopathy among individuals screened positive for diabetes in fi ve community-based eye camps in northern Karachi. J Ayub Med Coll Abbottabad 2006; 18: 1-13.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766-85.
Klein R, Klein BE, Neider MW, Hubbard LD, Meuer SM, Brothers RJ. Diabetic retinopathy as detected using ophthalmoscopy, a nonmydriatic camera and a standard fundus camera. Ophthalmology 1985; 92: 485-91.
American Academy of Ophthalmology Retina Panel. Preferred practice pattern guidelines: diabetic retinopathy. San Francisco, American Academy of Ophthalmology 2008 (http://one.aao. org/CE/PracticeGuidelines/PPP_Content).
Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CA, Davis M et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-82.
Th e Diabetic Retinopathy Study Research Group. A modifi cation of the Airlie House classifi cation of diabetic retinopathy (DRS report no. 7). Invest Ophthalmol Vis Sci 1981; 21: 210-26.
Furth AJ. Methods for assaying non-enzymatic glycosylation: a review. Anal Biochem 1988; 175: 347-60.
Al-Maskari F, El-Sadig M. Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. BMC Ophthalmology 2007; 7: 11-9.
Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) Eye Study, I. Invest Ophthalmol Vis Sci 2005; 46: 2328-33.
Zhang HX, Jia LL, Hou XH, Lu JX, Lu HJ, Du J et al. Prevalence of and risk factors associated with diabetic retinopathy in pre- diabetic and diabetic population in Shanghai community. Zhonghua Yi Xue Za Zhi 2009; 89: 1749-52.
Wahab S, Mahmood N, Shaikh Z, Kazmi WH. Frequency of retinopathy in newly diagnosed type 2 diabetes patients. J Pak Med Assoc 2008; 58: 557-61.
Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008; 115: 1869- 75.
Ossama AW, Haddad EI, Saad MK. Prevalence and risk factors for diabetic retinopathy among Omani diabetics. Br J Ophthalmol 1998; 82: 901-6.
Hu HY, Lu B, Zhang ZY, Mao LY, Song XY, Dong XH et al. An epidemiological study on diabetic retinopathy among type 2 diabetic patients in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 2007; 28: 838-40.
Dowse GK, Humphrey ARG, Collins VR, Plehwe W, Gareeboo H, Fared D et al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol 1998; 147: 448-57.
Collins VR, Dowse GK, Plehwe WE, Imo TT, Toelupe PM, Taylor HR. High prevalence of diabetic retinopathy and nephropathy in Polynesians of Western Samoa. Diabetes Care 1995; 18: 1140-49.
Haff ner SM, Mitchell BD, Moss SE, Stern MP, Hazuda HP, Patterson J et al. Is there an ethnic diff erence in the eff ect of risk factors for diabetic retinopathy? Ann Epidemiol 1993; 3; 2-8.
Hietala K, Carol F, Paula S, Per-Henrik G. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57: 2176-80.
Morello CM. Etiology and natural history of diabetic retinopathy: An overview. Am J Health Syst Pharm 2007; 64: S3-S7. Nugent DA, David MS, Huw BJ. A review of islet of Langerhans degeneration in rodent models of type 2 diabetes. Toxicol Pathol 2008; 36: 529-51.
Salehi M, Aulinger BA, D’Alessio DA. Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins. Endocr Rev 2008; 29: 367-79.
Screening for NIDDM. Why is there no national program? Diabetes Care 1994; 17: 440-44.
Kruger DF. Exploring the pharmacotherapeutic options for treating type 2 diabetes. Th e Diabetes Educator 2008; 34: 60S-65S.
Lu H, Yang Y, A llister EM, Wijesekara N, Wheeler MB. Th e identifi cation of potential factors associated with the development of type 2 diabetes. Mol Cell Proteomics 2008; 7: 1434-51.
Alberti KGMM. Th e costs of non-insulin-dependent diabetes mellitus. Diabetes Med 1997; 14: 7-9.
Dandona L, Dandona R, Naduvilath TJ, McCarty CA, Rao GN. Population based assessment of diabetic retinopathy in an urban population in southern India. Br J Ophthalmol 1999; 83: 937-40.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. Th e Wisconsin epidemiologic study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112; 1217-28.
Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997; 46: 1829-39.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-85.
Rohlfi ng CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defi ning the relationship between plasma glucose and HbA1c: analysis of glucose profi les and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-78.
Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A et al. Th erapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c: IOEZ Study Group. Diabetes Care 2000; 23: 1236-41.
Gugliucci A. Glycation as the glucose link to diabetic complications. J Am Osteopath Assoc 2000; 100: 621-34.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21-B29.
Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-73.
Pistrosch F, Koehler C, Wildbrett J, Hanefeld M. Relationship between diurnal glucose levels and HbA1c in type 2 diabetes. Horm Metab Res 2006; 38: 455-59.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260: 2864-71.
Klein R, Palta M, Allen C, Shen G, Han DP, D’Alessio DJ. Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol 1997; 115: 351-56.
O’Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfi k S et al. Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome? Eur J Vasc Endovasc Surg 2006; 32: 188-97.
Barak G, Hirsch B. Th e eff ects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998; 158: 134-40.
de Rekeneire N, Rooks RN, Simonsick EM, Shorr RI, Kuller LH, Schwartz AV et al. Racial diff erences in glycemic control in a well-functioning older diabetic population: fi ndings from the Health, Aging and Body Composition Study. Diabetes Care 2003; 26: 1986-92.
Lau CY, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. J Postgrad Med 2004; 50: 189-94.
Chatterjee MN, Shind R. Textbook of medical biochemistry. 5thed. New Delhi: Jaypee Brothers Medical Publications Ltd.; 2002.
Robbinson SM, Kumar V. Basic pathology. 4th ed. Philadelphia, PA: W.B. Saunders Company; 1989.
Dice JF, Walker CD, Byrne B, Cardie A. General characteristics of protein degradation in diabetes and starvation. Proc Natl Acad Sci 1978; 75: 2093-97.
Maillard LC. Action des acides amines sur les sucres: formation de melandides par voie methodique. Compte Rend Acad Sci (Paris) 1912; 154: 66-8.
Day JF, Th orpe SR, Baynes JW. Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum. J Biol Chem 1979; 254: 595-97.
Gasser A, Forbes JM. Advanced glycation: implications in tissue damage and disease. Protein Pept Lett 2008; 15: 385-91.
UK Prospective Diabetes Study Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
Omsland TK, Bangstad HJ, Berg TJ, Kolset SO. Advanced glycation end products and hyperglycemia. Tidsskr Nor Laegeforen 2006; 126: 155-58.
Zhang Q, Tang N, Schepmoes AA, Phillips LS, Smith RD, Metz TO. Proteomic profi ling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Proteome Res 2008; 7: 2025-32.
Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type 1 diabetes mellitus and collagen-linked fl uorescence. New Engl J Med 1986; 314: 403-8.
Goh SY, Cooper ME. Th e role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-52.
Stirban A, Negrean M, Götting C, Uribarri J, Gawlowski T, Stratmann B et al. Dietary advanced glycation endproducts and oxidative stress: in vivo eff ects on endothelial function and adipokines. Ann N Y Acad Sci 2008; 1126: 276-79.
Zhou H, Tan KCB, Shiu SWM, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transpl 2008; 23: 927-33.
Tan KCB, Chow WS, Ai VHG, Metz C, Bucala R, Lam KSL. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25: 1055-59.
Tan KCB, Chow WS, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004; 27: 233-28.
Anitha B, Sampathkumar R, Balasubramanyam M, Rema M. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. J Diabetes Complicat 2008; 22: 261-66.